Profusa和Mayo诊所合作伙伴在关键条件下推进实时组织氧气监测,Mayo在资金上进行投资。 Profusa and Mayo Clinic partner to advance real-time tissue oxygen monitoring for critical conditions, with Mayo investing financially.

Profusa与Mayo诊所合作,推进其Lumee连续组织氧气监测平台,目的是通过提供实时内部氧气数据,改善对心血管、肾脏和矫形疾病的护理。 Profusa has partnered with Mayo Clinic to advance its Lumee platform for continuous tissue oxygen monitoring, aiming to improve care in cardiovascular, renal, and orthopedic conditions by providing real-time internal oxygen data. 合作的对象是影响大的用途,包括慢性危及肢体的缺血症,支持监管进展,扩大技术范围,使其超越次级监测。 The collaboration targets high-impact uses, including chronic limb-threatening ischemia, supports regulatory progress, and expands the technology beyond subcutaneous monitoring. Mayo诊所拥有财务股份,其收益将重新投入其任务。 Mayo Clinic holds a financial stake, with proceeds reinvested into its mission. 这一行动是继最近出现逆向股票分割和Profusa股票跌至2.72美元之后采取的。 The move follows a recent reverse stock split and a drop in Profusa’s stock to $2.72.